- Our LinkedIn Page
- Our Twitter Feed
- Our Facebook Page
- Newsletter Subscribe to our e-newsletter. Current Issue
- Our Flickr Feed
- Our YouTube Feed
Tags
PUBLIC BIOTECH - Stats Biotechnology Industry Health Care biotech industry biotechnology patent BIOTECH Investment FDA IPO drug development Events BIO International Convention economy 2012 BIO International Convention Industry Analysis Partnering One-on-One's economic development PUBLIC BIOTECH - Stock performanceAuthors
- Abigail Hirsch
- Alan Eisenberg
- BIOtechNOW Editor
- Bruce Dale
- Celia Economides
- Colleen Lerro
- David Thomas, CFA
- George Goodno
- George MacDougall
- Jason Corum
- Jeff Joseph
- Jim Greenwood
- Karen Batra
- Kelly Cappio
- Lila Feisee
- Matt Carr
- Nathan Schock
- Paul Winters
- Paulina Ibarra
- Robbi Lycett
- Roy Zwahlen
- Sarah Sneeringer
- Sondra Behan
- Stephanie Fischer
- Stephen Marmaras
- Tracy Cooley
Latest From Biotech Now
Podcast: Dr. Karel Schubert, Bioscience Association of West Virginia
BIOtechNOW’s Tracy Cooley talks to Dr. Schubert of the Bioscience Association of West Virginia about biotech in West Virginia – major areas of growth, the outlook for growth of the industry within the state, and plans for the upcoming BIO International Convention. Download the podcast
Biotech should embrace open, online communication
At the upcoming 2011 BIO International Convention, we will issue a new opinion survey measuring public attitudes toward our industry and where government support for our industry ranks among other national priorities. While the survey found some interesting new data – sorry, you’ll have to wait until next week to get the details – we saw some results that are nearly the same each year we field this survey. We found that voters’ image of Read More >
House Patent Reform Bill, HR 1249, still has the Administration’s and BIO’s support
The White House, Office of Management and Budget, Office of Science and Technology Policy, and the United States Patent and Trademark Office have come out in support of HR 1249 and the Manager’s Amendment to the bill. The only caveat mentioned is that “final legislative action [should] ensure that the US Patent and Trademark Office’s (USPTO’s) fee collections are made fully available to support the nation’s patent and trademark system.” BIO also has come out in Read More >
BIO, Here We Come!
Angie Drakulich from PharmaTech Talk writes: Next week is the annual Biotechnology Industry Organization (BIO) Convention in Washington, DC. Many of our editorial team members will be there and we hope to see you. With a regulatory pathway for biosimilars underway in the United States, renewed conversations about regenerative medicine, and a booming biotech sector, the convention should be quite dynamic. Angie is part of our BIO Official Blog Program. Keep an eye on her Read More >
BIO Official Bloggers Program: Focus on Biosimilars
Andrew Williams wrote a second part to his original blog entry on 2011 BIO International Convention preview… This time his focus is on Biosimilars: For BIO attendees interested in learning more about the relatively new pathway for FDA approval of biosimilars, also known as follow-on biologics, there are several sessions devoted to the intricacies of the new law, or how the new legislation is impacting the BIO community. The biosimilar framework was introduced last year Read More >
